Cancer Drugs Fund requires further reform
Reliance on “real world” observational data undermines evidence base for clinical practice.
Auteurs principaux: | Grieve, R, Abrams, K, Claxton, K, Goldacre, B, James, N, Nicholl, J, Parmar, M, Parker, C, Sekhon, J, Smeeth, L, Spiegelhalter, D, Sculpher, M |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
BMJ Publishing Group
2016
|
Documents similaires
-
Huang Shu Yin funded for further study
par: Kwong Wah, Yit Poh
Publié: (2017) -
Huang Shu Yin Funded For Further Study
par: Kwong Wah, Yit Poh
Publié: (2017) -
MRE in NAFLD: promising but further validation is required
par: Ryan, J, et autres
Publié: (2018) -
Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals
par: Morrell, L, et autres
Publié: (2018) -
Bladder cancer: issues requiring further research
par: I. A. Rozhkov, et autres
Publié: (2024-09-01)